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Abstract
Breast cancer is one of the commonest cancers affecting women and oncoplastic breast sur-
gery has been firmly established as the mainstay of modern surgical treatment, replacing the 
traditional two-operation approach. Careful patient selection, relevance of effective com-
munication, patient education and navigating the complex decision-making process, are 
some of the topics covered in this chapter. Preoperative planning, implant selection, patient 
marking, importance of scar placement, marking and measuring the patient preoperatively, 
good theatre practice, technical tips for good cosmesis, and after care; are also discussed. 
A brief section on revision surgery following implant reconstruction, lipomodelling and a 
brief overview about breast implant associated anaplastic large cell lymphoma (BIA-ALCL) 
and multidisciplinary approach to modern management of breast cancer. It aims to serve as 
a guide to surgeons on current practice and achieving the ideal balance between oncological 
clearance of the cancer combined with good cosmesis and high levels of patient satisfaction.
Keywords: oncoplastic breast surgery, breast cancer, scar placement, patient selection, 
implant reconstruction, capsular contracture
1. Introduction
Surgical management of breast cancer has undergone significant evolutionary changes since 
Halstead’s description of radical mastectomy in 1882. Although Halstead was not credited 
for discovering this technique, his seminal paper published in the Annals of Surgery in 1894 
demonstrated a 20% survival benefit for the first time. Not surprisingly, the Halstead mas-
tectomy became the standard of care for the next several decades [1]. It took almost 70 years 
before quadrantectomy was considered a safe alternative to sacrificing the whole breast with 
long-term follow-up confirmed in the NSABP-B06 and Veronesi’s Milan I trial [2, 3].
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
The term oncoplastic breast surgery (OPBS) was first coined by Werner Audretsch in the 1980s, 
to describe rearrangement of breast tissue to fill the defect following a partial mastectomy and 
recreate the breast shape, with emphasis on cosmesis. Over the last three decades, oncoplas-
tic breast surgery has been established globally to encompass the ‘quadrant-per-quadrant’ 
approach to breast conservation advocated by Krishna Clough [4] and the Nottingham 
algorithm for therapeutic mammoplasty, championed by Douglas Macmillan and Stephen 
McCulley [5]. Introduction of biological mesh or acellular dermal matrix (ADM) in the mid-
1990s defined another watershed period with increasing mastectomy rates and immediate 
reconstruction. Steven Kronowitz from the MD Anderson Cancer Center in Texas, USA, 
introduced the concept immediate-delayed reconstruction in 2002 to help women avoid the 
trauma of mastectomy after waking up from surgery [6].
Today, women diagnosed with a new breast cancer are offered a range of treatment options 
within a multidisciplinary setting [7]. Breast cancer surgery is no longer a two-operation dis-
cipline, based on cancer dimension relative to breast size or patient choice of mastectomy 
versus breast conservation. An oncoplastic approach to modern management of breast cancer 
involves careful preoperative planning with other specialists such as radiologists, patholo-
gists and oncologists. A comprehensive breast assessment to determine the optimal breast 
conservation techniques is essential with emphasis on scar placement. All patients undergo-
ing mastectomy should have a discussion around reconstruction options, where appropriate.
Good communication skills and additional time during consultation, helps safeguard patient’s 
understanding of complex discussions around treatment. Early involvement of clinical psy-
chologists in selected cases can help anxious patients and exclude underlying mental health 
concerns. Heightened anxiety at the time of diagnosis could impact decision-making and 
alter clinical management, with potential for decision-regret after completing treatment. Well-
trained and dedicated breast care nurses are indispensable in a modern surgical breast unit [8]. 
Providing well designed and simple information leaflets to read outside the stressful environ-
ment of the doctor’s office, can help patients navigate the complexity of the decision-making 
process. These combined efforts serve to demystify the various treatment options, empower 
women with the concept of ‘patient choice’ and ensure informed consent.
This chapter aims to present aspects of modern oncoplastic surgical approach in the treatment 
of breast cancer, with emphasis on implant-based reconstruction.
2. Oncoplastic breast surgery
Breast conserving surgery, often referred to as lumpectomy or wide local excision (WLE), is the 
standard treatment for the majority of early invasive and in situ breast cancer [9]. Screening pro-
grams have been established for over 60 years with early detection of small and non-palpable can-
cers, allowing smaller resection volumes and avoiding the need for mastectomy in most women.
2.1. Wide local excision (WLE)
Simple excision of the tumour with reasonable margins forms the basis for lumpectomy 
or wide local excision (WLE) and is appropriate for majority of screen-detected in situ or 
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invasive cancer. Traditional approach of scar placement over the tumour site, without ade-
quate mobilisation of skin or approximation of breast parenchyma and leaving the cavity to 
fill with seroma, was responsible for poor cosmetic outcomes in the past [10]. Volume of exci-
sion relative to breast size, location of the tumour and re-excision surgery are independent 
risk factors for poor cosmesis (Figure 1).
In a recent clinical study correlating resection volumes and tumour location with clinical 
photographs of patients 2 years after completing radiotherapy, was assessed by a panel and 
scored. Despite the small sample size, there was significant variation in the cosmetic results 
between oncoplastic surgeon and general breast surgeons (Figures 2 and 3) [11].
Oncoplastic breast surgery involves careful preoperative planning with dedicated breast 
radiologists in the MDT to confirm adequate clearance of the tumour from the overlying skin. 
Figure 1. Poor cosmetic results from breast conserving surgery.
Figure 2. Clinical study results poor cosmetic outcome.
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This allows aesthetically placed scars which could be remote from the tumour site and avoids 
disfiguring scars across the breast mound. Mobilisation and approximation of the breast 
parenchyma after removal of the tumour can help avoid unsightly tethering of the skin to the 
underlying muscle following radiotherapy (Figure 4). These simple measures can help ensure 
good cosmesis for patients whilst obtaining oncological clearance of the tumour. Almost all 
cases of wide local excision (WLE) are achievable via a circumareolar approach, which heals 
well with minimal scarring on the breast mound (Figure 4).
2.2. Volume displacement techniques
A number of volume displacement and volume replacement techniques in a quadrant-per-quadrant 
approach to treating breast cancer, have been described by Clough [4]. Careful assessment of the 
breast size, shape and density combined with preoperative estimation of resection volumes, 
helps determine the optimal choice of procedure. Two of the commonly used volume displace-
ment techniques, Benelli (round block) and therapeutic mammoplasty, are discussed below.
Figure 4. Wide local excision using circumareolar incision.
Figure 3. Clinical study results good cosmetic outcome.
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2.2.1. Benelli/round-block mammoplasty
The Benelli or round-block mammoplasty is a versatile technique used to excise tumours 
from various quadrants in the breast and reposition the nipple in the desired location at the 
end of the procedure [12]. This is essentially a variation of the tennis racquet technique, but 
without the ‘handle’. The tennis racquet is a useful option if the skin overlying the tumour 
needs to excised and prevents the nipple from being tethered towards the index quadrant 
after radiotherapy and accentuating the asymmetry compared to the contralateral breast. The 
Benelli mammoplasty can also be used to reduce the skin envelope if required, depending on 
the volume of resection and the size of the patient’s breasts.
Use of bilateral round-block/Benelli mammoplasty is illustrated in this 70-year-old patient with 
aged silicone implants and a new symptomatic LEFT breast cancer. The implants were more 
than 35 years old with MRI evidence of intra- and extracapsular rupture and silicone leakage 
(Figure 5). The tumour located in the LEFT breast at 6:00/50 mm from the nipple was excised 
with safe margins. Capsulectomy and removal of the aged implant was achieved through the 
same incision and redundant skin excised using the Benelli technique.
MRI proven ruptured aged silicone implant in the opposite breast was also removed via a 
similar approach with good postoperative symmetry (Figures 6 and 7).
2.2.2. Therapeutic mammoplasty (TM)
Adjuvant radiotherapy in large breasted women after WLE can be difficult due to the volume 
of breast tissue, degree of ptosis and in some cases need to be delivered with the patient 
prone. Therapeutic mammoplasty (TM) combines breast reduction surgery and WLE to provide 
an opportunity for these women to achieve the desired smaller breasts, as part of their can-
cer treatment [13]. More importantly, breast reduction surgery after previous radiotherapy 
increases the risk of wound related complications and should only be undertaken by expe-
rienced plastic and oncoplastic breast surgeons. For women with large breasts, TM allows 
large excision volumes with excellent margins, beyond the conventional threshold for simple 
Figure 5. Pre-op MRI demonstrating tumour and silicone leak.
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WLE. Secondary pedicles of tissue which are usually excised as part of breast reduction sur-
gery are used to fill the WLE defect. Recovery from surgery is similar to simple mastectomy 
without any delay in adjuvant therapy (Figures 8 and 9).
The nipple-areolar complex (NAC) can be sacrificed in older patients to minimise the risk of 
nipple necrosis and wound complications. The NAC may also need to be removed when the 
tumour is located close to the nipple to ensure oncological safe margins. TM in this setting 
Figure 7. Post-op round block mammaplasty.
Figure 6. Pre-op capsular contracture and Benelli mammaplasty.
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provides a better alternative to mastectomy for these patients and avoids large and heavy 
external prosthesis to match the contralateral normal breast [14]. In this example, an 83-year-
old lady with large ptotic J-cup sized breasts presented with symptomatic 45 mm RIGHT 
breast cancer @12:00, with associated 110 mm of suspicious calcification extending to the 
nipple (Figure 10).
Bracketed hook-wire was used preoperatively to mark the extent of calcification to ensure safe 
margins and confirmed on final histology (Figure 11). Despite the extensive nature of surgery, 
Figure 8. Pre-op therapeutic mammaplasty.
Figure 9. Post-op therapeutic mammaplasty.
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TM confers a high degree of patient satisfaction, without any delay in adjuvant treatment or 
significant morbidity; even in older patients (Figure 12). Well-trained breast care nurses are 
essential for preoperative patient education and managing complex wounds after surgery.
2.3. Volume replacement techniques
Several volume replacement techniques, such as mini-latissimus dorsi (LD), lateral thoracic artery 
perforator (L-TAP), intercostal artery perforators (I-CAP), serratus anterior artery perforator 
Figure 10. Pre-op hook-wire and markings for TM.
Figure 11. Bracketed hook-wire.
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(SAAP) and thoracodorsal artery perforator (T-DAP) flaps have been described to fill large 
defects created by WLE. Mini-LD flaps should be avoided in this setting and the latissimus dorsi 
muscle preserved as salvage tissue cover for complex locally advanced and recurrent disease, for 
lower pole support instead of mesh or as definitive reconstruction option following mastectomy.
2.3.1. Autologous adipo-dermal perforator flaps
The original pedicled perforator flaps described by Mustafa Hamdi in 1984 included tho-
racodorsal artery perforator (T-DAP), intercostal artery perforator (ICAP), serratus anterior 
Figure 12. Post-op TM sacrificing the NAC.
Figure 13. Pre-op marking of L-TAP and Li-CAP vessels with USS Doppler.
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artery perforator (SAAP) and superior epigastric artery perforator (SEAP) flaps for immediate 
or delayed partial breast reconstruction or as adjuncts to implant reconstruction [15]. These 
versatile perforator flaps can be used to fill parenchymal defects in almost any quadrant of the 
breast. This technique allows large excision volumes to ensure good resection margins and 
the size of the flap can be adjusted to achieve good cosmesis.
The Li-CAP and T-DAP vessels are marked preoperatively with handheld Doppler’s or USS colour 
Doppler mode prior to skin incision (Figure 13). These flaps utilise the skin and subcutaneous fat 
in the lateral chest wall and are raised on small and consistent perforator vessels (Figure 14).
Figure 14. Perforator vessels for Li-CAP flap.
Figure 15. Lateral scar after volume replacement with Li-CAP flap.
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The length of the scar is variable depending on the volume required for replacement and is 
mostly hidden within the bra, with less donor site morbidity compared to traditional LD flap 
(Figure 15). These autologous perforator flaps are robust and appear to tolerate radiation 
therapy without significant volume loss. They serve as ideal volume replacement options for 
high-risk patients such as diabetics, smokers and older patients, without compromising flap 
viability.
Two-stage procedure is recommended by the Nottingham group, particularly if the extent 
of disease is unclear on diagnostic imaging. WLE and axillary surgery is completed as the 
first stage and the cavity filled with water to keep the cavity patent. Once the histology con-
firms adequate margins, patients can undergo the second stage to recruit the perforator flap 
(Figures 16 and 17). If the pathology demonstrates more extensive disease than originally 
Figure 16. After first stage WLE cavity filled with water.
Figure 17. Post-op photo after volume replacement with Li-CAP.
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anticipated, patients could be offered re-excision of margins or conversion to mastectomy. A 
two-stage procedure helps avoid wasting a good flap in the initial stage and serves as a bridge 
to definitive surgery.
3. Mastectomy and breast reconstruction
Simple mastectomy is a good surgical option for elderly patients, women living in remote 
areas with limited access to radiotherapy and those who do not wish to undergo immediate 
reconstruction (Figure 18). Increasing number of women is choosing to have mastectomy 
with immediate reconstruction instead of breast conservation [16].
‘A good reconstruction starts with a good mastectomy’ is an often quoted by oncoplastic breast 
surgeons and advocated by the Nottingham Breast Unit, UK. Historically, free-transverse rec-
tus abdominis (TRAM) flap or deep inferior epigastric artery perforator (DIEP) flap has been 
regarded as the gold standard for breast reconstruction [17]. This is a significant undertaking 
for patients with prolonged hospital stay, delayed recovery and donor site morbidity. Not 
surprisingly, the incidence of these complex autologous flaps has remained static compared 
to the exponential increase in implant reconstruction over the past three decades [18].
Latissimus dorsi (LD) flap with implant (Figure 19) was a common reconstruction procedure 
post mastectomy in the 1980s and 1990s, due to the robust nature of the flap, consistent aes-
thetic results and acceptable donor site morbidity compared to TRAM flap. The incidence of 
LD has declined with the increasing incidence of implant reconstruction in the late 1990s and 
early 2000s. More recently, there appears to be a resurgence of LD flaps, according to MD 
Anderson data [18].
Figure 18. Right simple mastectomy.
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The chest wall perforator flaps (L-TAP and Li-CAP) can also be used as complete autolo-
gous flap reconstruction following mastectomy and was first described by Losken and 
Hamdi in 2009 [19, 20]. This is a safe reconstruction option in the high-risk candidates, 
such as smokers, raised BMI, diabetics, or in patients where implant or complex autolo-
gous reconstructions are relatively contraindicated due to post-operative radiotherapy 
(Figures 20 and 21).
Figure 19. Right mastectomy with immediate LD flap and left mastectomy with implant reconstruction.
Figure 20. Pre-op marking bilateral mastectomy following neoadjuvant chemotherapy.
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4. Mesh versus autologous tissue for lower pole support
Since its introduction in the late 1990s, the acellular dermal matrix (ADM), derived from 
various biological sources, has been responsible for the meteoric rise in mastectomy rates 
with implant and tissue expander reconstruction [21]. There is a substantial global market for 
ADM or biological meshes currently manufactured from porcine dermis, foetal or neonatal 
bovine dermis, bovine pericardium and human cadaveric skin.
Parallel to the success of ADM, there has also been an increase in synthetic mesh used for 
lower pole support in implant and tissue expander reconstruction (Table 1). The main driver 
for synthetic mesh has stemmed from cost associated with ADM, reports of ‘red breast syn-
drome’ (RBS) and higher seroma rates [22]. The ‘red breast syndrome’ (RBS) is a unique 
delayed hypersensitivity reaction to ADM and presents as erythematous skin overlying the 
mesh. Despite lack of febrile response and normal laboratory markers which characterises 
RBS, patients often receive increasing amounts of unnecessary antibiotics, due to concerns for 
the underlying implant [23].
The absorbable synthetic TIGR mesh produces a stable IMF after 18 months post-reconstruction 
compared to ADM with lower implant loss rates and half the volume of seroma output in the 
author’s experience (Figure 22) [24].
In one of the largest reported series of TIGR mesh since May 2014, a total of 138 cases in 
87 consecutive patients undergoing immediate or delayed reconstruction were recently pre-
sented in the Annual Scientific Congress of RACS (Royal Australasian College of Surgeons) in 
Sydney, Australia, in May 2018. There was no 90-day post-operative implant loss reported in 
the author’s series, with three cases of delayed implant loss at 5, 12 and 28 months following 
radiotherapy. There were no cases of skin flap necrosis or RBS in this series [25]. These results 
Figure 21. Post-op bilateral skin-sparing mastectomy with immediate Li-CAP flap reconstruction.
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are similar to a recent publication by Pompei et al., with 49 consecutive patients and 60 TIGR 
mesh used over a 2-year period with only 1 implant loss due to skin necrosis [26].
The following is the example of nipple-sparing mastectomy, axillary node clearance with 
immediate expander-implant reconstruction in a 54-year-old woman with previous breast 
Mesh ADM/synthetic Source Manufacturer
Strattice ADM Porcine LifeCell Corp.
Permacol ADM Porcine Covidien
SurgiMend ADM Foetal/neonatal bovine 
dermis
Integra LifeScience Ltd.
VERITAS ADM Bovine pericardium Synovis Surgical innovations, St. Paul, 
MN, USA®
Alloderm ADM Human cadaveric skin LifeCell Corp. Branchburg. N.J
Epiflex ADM Human cadaveric skin Deutsches Institut für Zell-und 
Gewebeersatz [DIZG] gGmbH, Berlin, 
Germany
ALLOMAX™ ADM Human cadaveric skin Bard, Inc.
DermaMatrix® ADM Human cadaveric skin Synthesis CMF/Johnson & Johnson
TIGR Synthetic absorbable Novus Scientific
TiLoop® Bra Synthetic titanium 
coated
pfm medical, Cologne, Germany
SERAGYN BR® Synthetic SERAG-WIESSNER GmbH & Co. KG
Table 1. Current list of ADM and synthetic mesh used for implant and tissue expander reconstruction.
Figure 22. Nipple-sparing mastectomy via inframammary fold incision and retropectoral implant reconstruction and 
TIGR mesh.
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implants and multifocal triple negative breast cancer with nodal involvement (Figures 23–25). 
Patient developed significant lymphangitis and cellulitis of the breast skin envelope 28 months 
after radiotherapy with explantation and request for contralateral symmetrising mastectomy.
The two-stage tissue expander (TE) reconstruction with limited mobilisation of the serratus 
muscle and pectoralis major was the standard procedure prior to ADM or synthetic mesh 
for lower pole support. The results were often inconsistent with high-riding TE and need for 
revision surgery. The nipple-areolar complex (NAC) and most of the redundant mastectomy 
skin envelope in medium to large breasted women had to be sacrificed due to limited capacity 
of the muscle pocket. Stable inframammary fold (IMF), preservation of the native mastectomy 
skin flap, retropectoral direct to implant reconstruction with predictable aesthetic results and 
relatively short learning curve; are some of the reasons for the exponential global uptake of 
biological and synthetic mesh. Shorter operative time and hospital stay, earlier recovery and 
return to normal function with less donor site morbidity and high patient satisfaction rates 
have also contributed to its popularity.
More recently, use of prepectoral implant with complete ADM coverage appears to have good 
outcomes with high levels of patient satisfaction [27]. ‘Animation’ or variable movement of the 
reconstructed breast when tensing the pectoral muscles is a recognised issue with retropec-
toral implant reconstruction (Video: https://mts.intechopen.com/download/index/process/270/
authkey/a5ea41ce666a3344dd2e459c34b3d46a). The prepectoral technique circumvents the 
‘animation’ problem and patients are able to return to physical activity without the usual 
restrictions of retropectoral surgery.
Any contour defect due to capsular contracture or tethering of skin to the pectoral fascia 
above the implant, can be addressed with fat grafting; either at the index operation or as 
Figure 23. Left nipple-sparing mastectomy with immediate expander-implant reconstruction.
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a delayed procedure. In very slim patients without significant subcutaneous body fat, pre-
pectoral approach may be challenging with ‘ghosting’ effect from the underlying implant. 
Braxon ADM (designed and patented by DECOmed s.r.l.) is a specially designed biologi-
cal mesh, which offers complete coverage of the implant for prepectoral placement with the 
added convenience of suturing the mesh directly onto the chest wall.
Figure 25. Bilateral mastectomy post explantation and request for delayed reconstruction.
Figure 24. Cellulitis 28 months after radiotherapy.
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Despite the significant global trend towards ADM and synthetic mesh-assisted implant recon-
struction, recent years have also witnessed a resurgence in autologous tissue for inferior pole 
support, such as scar-less mini-LD flap and T-DAP flap. ADM associated ‘red breast syn-
drome RBS’, less than anticipated reduction in capsular contracture, higher seroma rates and 
secondary infection with implant loss; may account for this parallel rise in autologous tissue 
support. Some permanent synthetic meshes can result in higher rates of capsular contracture 
with firm tissue in the lower pole, resulting in long-term discomfort. Continued technological 
advances in lightweight synthetic mesh which integrate better with the host tissue, could help 
improve cosmetic outcomes for patients.
5. Tissue expander versus direct to implant reconstruction
The two-stage tissue expander (TE) is the standard reconstruction technique following skin-
sparing or nipple-sparing mastectomy in most Western countries. TE is a safer option than 
direct to implant, particularly when there is uncertainty about the need for post-operative 
radiotherapy. Many surgeons continue to advocate the two-stage tissue expander reconstruc-
tion due to concerns about skin flap viability and risk of implant failure. Use of TE allows the 
mastectomy skin flap to heal without undue tension and risk of necrosis.
Two-stage tissue expander reconstruction is an option for women who wish to achieve larger cup 
size after breast reconstruction (Figures 26 and 27). The expander is replaced with a definitive 
implant as a second operation after completion of adjuvant therapy (such as chemotherapy). It is 
possible to deliver radiotherapy in women with tissue expanders or implants without compro-
mising treatment. Patients need to be counselled about the increased risks of wound breakdown, 
implant infection and reconstruction failure in this setting. Use of adjustable expander-implants 
with a mini-remote port placed outside the radiotherapy field is helpful in reducing CT artefact 
during planning. There is a wide variation in the delivery of radiotherapy depending on centres. 
Figure 26. Right two-stage TE and left prophylactic TE reconstruction.
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Many radiation oncologists are reluctant to deliver treatment in the presence of tissue expanders 
with integrated ports due to the large area of the metal backing in the port, uncertainty about 
treatment delivery in the area and concerns with raised temperatures and skin burn from treat-
ment. Despite the higher risks, two-stage TE serves as a bridge to definitive reconstruction after 
completion of radiotherapy and helps preserve the mastectomy skin flap.
In patients who have not had radiotherapy, minor adjustments in the pocket or IMF is achiev-
able in the second stage, but the basic footprint of the reconstruction is designed at the pri-
mary operation. Patients should be measured carefully in the clinic prior to surgery as a guide 
to ordering appropriate sized implants.
Newer technology such as SPY Elite system for intraoperative monitoring of skin flap viability 
and vascular supply and use of newer diathermy devices such as PlasmaBlade (Medtronic 
plc. ®), which ensures lower tissue temperatures during dissection, can help minimise the 
risk of skin flap necrosis. Basic surgical principles of gentle tissue handling, avoiding undue 
traction of the skin flap or use of traumatic instruments at the skin edges, keeping the patient 
warm perioperatively, avoiding unnecessarily thin mastectomy skin flaps, resting the flap 
regularly and ensuring tension-free closure of the skin over the implant reconstruction; are 
simple ways to avoid skin flap necrosis.
6. Nipple-sparing and skin-sparing mastectomy
The safety of nipple-sparing mastectomy, depending on tumour location, has been adequately 
established for both in situ and early invasive breast cancer [28]. Careful preoperative assess-
ment to ensure adequate clearance of the skin and nipple from the tumour site helps to ensure 
reasonable margins and reduce the risk of recurrence.
Figure 27. Final result replacement left TE with implant.
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Skin-sparing mastectomy is a simpler option in central tumours involving the NAC (Figure 26). 
This is also the commonest approach utilised by general breast surgeons when undertaking 
combined procedures with their plastic surgery colleagues. The volume of skin excised and 
scar placement is often dictated by the plastic surgeon. Upfront sentinel node biopsy is carried 
out as a separate operation to accurately stage the axilla, prior to any reconstruction. If the 
axillary nodes are involved with metastatic cancer, patients are more likely to require post-
operative radiotherapy. In this situation, plastic surgeons may decline immediate implant or 
autologous reconstruction such as LD or DIEP flap, due to poor aesthetic outcomes and higher 
reconstruction failure rates after radiotherapy [29, 30].
Nipple-sparing mastectomy with direct-to-implant reconstruction in the immediate set-
ting is a safe option in experienced hands and avoids the need for a second procedure 
(Figures 28 and 29).
The IMF incision confers adequate access for undertaking mastectomy, axillary surgery and 
placement of mesh for lower pole support of the implant. Temporary sizers help to determine 
the optimal implant size and confirm tension-free wound closure. This is an important step as 
the mastectomy skin envelope should drape the implant rather than stretched across it. The 
mastectomy skin flap relies on the fine sub-dermal capillaries for its blood supply. This could 
potentially be compromised with excessively large implants and tight closure of the IMF and 
result in skin flap necrosis.
Gentle tissue handling, avoiding excessive forceful retraction and preserving the subcutaneous 
fat layer during mastectomy, are some of the essential steps in preserving the integrity of the 
mastectomy skin flap. Poor technique is probably the commonest cause for skin flap necrosis 
and is often reflective of inadequate training and failure to adhere to basic principles outlined 
above. The product often gets blamed for inferior outcomes in some of the online publications.
Figure 28. Post-neoadjuvant chemo BL nipple-sparing mastectomy.
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A single drain is left in the space between the skin flap and the mesh to remove the seroma 
following mastectomy. The drain is left in until the daily output slows down to approximately 
30 ml/day. Build-up of seroma can cause additional tension along the wound edge or affect 
circulation of the skin flap and must be monitored carefully in the early post-operative period. 
Seroma formation is much lower with TIGR mesh compared to some ADM’s in the author’s 
own presented series [24].
Careful patient selection is important and direct implant reconstruction is best avoided in 
smokers and high-risk candidates such as diabetics and women with raised BMI. It is essential 
to have a well-trained, dedicated breast care nurse who is qualified in wound care manage-
ment. Educating patients about postoperative recovery and precautions about physical activi-
ties in the initial months after surgery helps ensure good cosmesis and minimises the risk of 
wound-related complications.
7. Skin-reducing mastectomy, with or without nipple preservation
Nipple-sparing mastectomy is usually carried out via the IMF approach in small- to medium-
sized breasts. It is possible to achieve nipple-sparing mastectomy in larger patients who wish 
to remain the similar size, via the same approach. In younger patients, some degree of skin 
contraction is achievable but decline in collagen levels with normal ageing process can result 
in redundant skin flaps.
Most large breasted women, however, are keen to achieve a smaller reconstructed breast 
volume and skin-reducing mastectomy techniques can be used with immediate implant 
reconstruction, with or without nipple preservation. Patients need to be cautioned about 
Figure 29. Six months after retropectoral implant reconstruction and TIGR mesh.
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a higher than average risk of nipple necrosis with complex surgery. A skin reducing wise-
pattern mastectomy using bi-pedicle dermal flap to maintain vascular integrity of the NAC 
is described by the author and recently accepted for publication (Figures 30 and 31). This 
technique is a variation of the previously published modified Letterman technique [31] and 
early results of the author’s series were presented as poster at the Leura 8 Conference in 
Sydney 2016.
This technique can be used in large breasted women for immediate implant-based and autolo-
gous reconstruction. It is also possible to use this technique for revision surgery to address 
any redundant skin flap after previous implant reconstruction. The bi-pedicle dermal flap 
provides variable length for adjusting the nipple height to the desired position based on the 
final breast volume and maintains dual vascular supply to the NAC. The dermal flap also pro-
tects the incision site from the underlying implant and mesh and minimises risk of implant 
infection or reconstruction failure.
Tension-free closure of the wound helps reduce pressure on the skin flap and NAC from 
the underlying implant and protects the fine sub-dermal capillaries supplying the skin flap 
following mastectomy (Figure 32). Use of drains to anticipate any seroma formation and post-
operative swelling also helps mitigate the additional risk at the suture line and viability of the 
NAC.
Goldilocks mastectomy with implant reconstruction, using a wise-pattern skin incision and 
dermal flap for lower pole support has been previously described. The nipple vasculature 
is maintained on the superior pedicle only and is best avoided in older patients or high-risk 
women such as smokers, diabetics and raised BMI [32].
Figure 30. Pre-operative skin-reducing mastectomy.
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Figure 31. Wise pattern skin-reducing nipple-sparing mastectomy using bi-pedicle dermal flap and implant reconstruction 
with TIGR mesh.
Figure 32. Viable NAC at time of skin closure.
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8. Silicone versus saline implants
The first silicone implants used in breast surgery were designed in 1961 by Thomas Cronin 
and Frank Gerow, two American Plastic surgeons. Prior to this, a variety of products were 
used to fill the cavity, including the practice of injecting silicone into the breast tissue in the 
1950s and 1960s. Over 50,000 women in the US who underwent this procedure ended up 
with silicone granuloma and hardening of the breast and many even requiring mastectomy. 
Early designs of these implants caused significant capsular contracture, a condition due to the 
host tissue creating a shell around the implant which gets progressively hard and uncomfort-
able. The Baker classification of grading capsular contractures from I to IV is often used as 
standardised measure of assessing the degree of hardness and aesthetic outcome [33]. The 
true incidence of capsular contracture after breast implant augmentation is quoted between 
8–15%, although the incidence following breast reconstruction may be higher. The exact cause 
of capsular contracture is not known and range from biofilm secondary to subclinical infec-
tion and inflammatory foreign-body type reaction. The incidence of capsular contracture has 
been found to be less with textured implants compared to smooth implants.
Early manufacturers found the use of polyurethane foam coating on the shell of the implants 
helped minimise the risk of capsular contracture. This practice was discontinued due to con-
cerns of potential health risk from 2,4-toluenediamine (TDA), a carcinogenic by-product of the 
chemical breakdown of polyurethane. The FDA banned the use of silicone implants in 1992 
during which time saline implants were the predominant prosthetic device used in America. 
Coincidentally, silicone implants continued to be used across Europe and Australasia despite 
the FDA ban. Saline implants were first designed in France and introduced in 1964 as a medi-
cal prosthetic device but caused more wrinkling with higher rates of capsular contracture 
and accelerated lower pole stretch, making it less desirable as a reconstruction option post 
mastectomy. The FDA eventually lifted its ban in 2006 following extensive research confirm-
ing safety of silicone implants.
Silicone implants came under media scrutiny again in 2017 following reports of Breast 
implant associated–Anaplastic Large Cell Lymphoma (BIA-ALCL). This has resulted in an 
almost knee-jerk response to revert back to saline implants in some centres. The actual risk of 
BIA-ALCL is very low and believed to be related to heavily textured implants, although few 
cases have been reported with smooth implants as well. As of September 2017, 409 cases of 
BIA-ALCL have been reported worldwide with 14 deaths. Current risk of developing BIA-
ALCL with silicone implant use is quoted between 1: 30,000 and 1: 50,000. Manufacturers 
continue to design newer and lower textured implants in an attempt to counter the growing 
public concern around ALCL. The historic issues with saline implants of increased capsular 
contracture, rotation/flipping of the implant, rupture and migration remain with its use and 
could result in increased revision rates.
Decision regarding saline or silicone implants should be based on clinical indications, 
rather than fear of ALCL associated with textured implants. Patients should be advised 
about the small risk of BIA-ALCL and that the majority of cases are diagnosed early. Typical 
presentation is a sudden build-up of fluid around the implant and 9–13% of delayed seroma 
may be ALCL related. The timeframe for ALCL is usually 15 months to 5 years post implant 
surgery.
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Ultrasound-guided aspiration of the fluid tested for CD-30 on IHC, is the definitive diag-
nostic test for BIA-ALCL. PET scan is recommended to stage the patient and in early stage 
disease, explantation with complete en-bloc capsulectomy including the posterior wall, 
combined with excision biopsy of lymph nodes is recommended. Due to the rarity of this 
condition, the Australasian Society of Plastic Surgeons (ASPS) advice that only few dedicated 
labs undertake the test and only specialist surgeons perform the operation to ensure good 
outcomes for patients. Patients should be reassured that stages I and II are completely cur-
able. Chemotherapy in advanced cases and CD-30 targeted therapy in refractory cases have 
shown encouraging results. Standardised guidelines for the diagnosis and management of 
BIA-ALCL have been published by NCCN in 2016 [34].
Choice of anatomical versus round implants requires careful assessment of the patient’s 
body habitus, chest wall shape and width, native breast shape and discussion regarding the 
desired final outcome. In a cancer setting, it is worth being cautious about having a carte 
blanche approach to implant options. With medium sized breasts, patients should be encour-
aged to remain approximately the same cup size and additional cleavage is achievable with 
round versus anatomical implants. Patients should be cautioned about using the appropriate 
implant size as determined by the mastectomy skin envelope, to avoid complications of skin 
flap necrosis or wound breakdown (Section 6).
It is advisable to order a range of implants to choose from at the time of surgery. Use of sizers 
intraoperatively can help determine ideal sized implants to ensure tension-free closure of the 
wound. Surgeons embarking on their career in oncoplastic breast surgery should become 
familiar with the range of commercially available implants in terms of height, width and 
profile.
9. Revision surgery and lipomodelling
Capsular contracture is a well-documented risk associated with implant reconstruction and 
patients should be cautioned prior to surgery. The risk of capsular contracture is higher with 
saline and smooth implants compared to textured or polyurethane-coated implants and in 
sub-muscular placement. The incidence is approximately 10–15% and is the commonest rea-
son for revision surgery. Increasing role of lipomodelling to help reduce the risk of capsular 
contracture and address contour defects from previous surgery can minimise the extent or 
complexity of revision surgery [35, 36]. Patients should be advised that lipomodelling is dif-
ferent from liposuction and should not expect to achieve significant weight reduction after 
this procedure. There is a limited volume of lipofilling that can be achieved during revision 
surgery, taking care to avoid excess tension and risk of fat necrosis. Safety of fat grafting has 
now been adequately established and serves to improve vascularity to the thin mastectomy 
flaps, especially after previous radiotherapy.
It is important to set patient expectations at the outset and emphasise that the aim of onco-
plastic breast surgery is not to achieve perfection, but rather obtain as close to a normal 
appearing breast as possible. Patients should also be cautioned that each revision surgery 
carries additional risks to the native skin flaps and that the aesthetic outcome may not be as 
good as the initial results in some cases.
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10. Patient choice versus treatment options
Before the advent of oncoplastic breast surgery, limited options between WLE and simple 
mastectomy made surgical consultations around breast cancer treatment relatively simple. 
The ability to offer a wide range of surgical options does not warrant outlining the entire list 
to patients during their initial visit. This is particularly relevant when patients are struggling 
with heightened anxiety around their cancer diagnosis. There is good evidence to suggest 
that patients only retain a fraction of the complex discussion undertaken in a doctor’s office. 
It requires experience and skill to navigate the complexity of information offered during the 
initial consultation and to gauge the patient’s level of understanding.
It is important to actively enquire if the patient is satisfied with the shape and size of her 
breasts at the time of diagnosis, even before instigating any discussions around OPS. In 
this example, a 67-year-old patient with a new screen-detected 80 mm area of DCIS in the 
upper outer quadrant was recommended mastectomy with sentinel node biopsy by the MDT 
(Figure 33).
The patient was keen on immediate reconstruction but raised BMI with ptotic native breast 
and social circumstances made implant or autologous reconstruction challenging with need 
for symmetrising contralateral procedure (Figure 34). Further discussion with the patient 
and option for extended WLE with SNB and immediate Li-CAP autologous dermal-adipose 
Figure 33. Mammogram with DCIS.
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flap for volume replacement served as the ideal option in this patient. She was well enough 
to be discharged after 2 days in hospital without any delay in adjuvant radiotherapy. The 
lateral scar remains hidden within the bra line with good functional status, low donor site 
morbidity, return to normal activities and high satisfaction rates with aesthetic outcomes 
(Figure 35).
Figure 34. Pre-op left breast DCIS.
Figure 35. Post-op extended WLE with Li-CAP volume replacement.
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Choice of reconstruction options may be limited by patient factors like smoking status. Implant 
and autologous reconstruction such as DIEP are not routinely offered to women who smoke, 
due to unacceptably high rates of wound complications and reconstruction failure. There are 
many centres where implant reconstruction is routinely offered to women who smoke, but 
patients need to be clearly informed about the high risk of wound related complications and 
implant failure. Smoking causes vasoconstriction with altered bacterial flora secondary to 
tissue hypoxia and is believed to be responsible for the poor wound healing (Figure 36). This 
could negatively impact on younger patients due to delays in adjuvant chemotherapy.
Raised BMI is an independent risk factor for higher seroma rates, increased wound infection 
and anaesthetic related issues. Implant reconstruction in larger women can be difficult due to 
limited choices of implants to accommodate the wide chest wall dimension. The shape of the 
reconstructed breast is governed by the shape and size of implant and symmetrising surgery 
is often required to address the large and ptotic contralateral breast. The risks for wound 
complications are higher if this is combined with cancer surgery and could delay adjuvant 
therapy. In these patients, the autologous Li-CAP perforator flap or Goldilocks mastectomy 
(Section 2.3.1) serves as a useful and safer alternative for immediate reconstruction after 
mastectomy and appears to tolerate radiotherapy well. Patients need to be cautioned about 
prolonged seroma formation with both these options.
There has been a global increase in the incidence of contralateral prophylactic mastectomy 
(CPM) in the last decade and has been often labelled the ‘Angeline Jolie effect’. Over the same 
timeframe, a well-cited Wall Street Journal article from July 2015 has resulted in increasingly 
number of women taking ownership for their treatment and demanding a double mastec-
tomy [37]. Anxiety around perceived cancer recurrence, poor diagnostic yield with standard 
Figure 36. Smoking-related complication.
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imaging in lobular cancers, family history and discomfort from multiple biopsies and repeated 
mammograms; are some of the reasons for women seeking CPM. More recently, the surgical 
community has been criticised for ‘bowing down’ to patient request for double mastectomy 
when diagnosed with a new cancer. Some women may feel strongly about undergoing one 
operation, which could help reduce anxiety around repeated imaging and biopsy. It is impor-
tant to carefully understand the individual patient’s reasons for considering CPM. There 
is good evidence that CPM does not confer survival benefit and risk of contralateral breast 
cancer for the vast majority of patients is relatively low. Patients need to be clearly explained 
about the higher risk of wound related complications, delayed recovery and impact on adju-
vant treatment with low benefit in terms of survival and recurrence. Despite this, if they con-
tinued to feel strongly about bilateral mastectomy with or without reconstruction, it would be 
reasonable to offer them the option of CPM (Figures 37 and 38).
It is important to clearly document all aspects of preoperative discussions in the clinical 
records due to potential medicolegal implications.
There is potential for ‘clinician bias’ with even experienced surgeons which could alter the 
direction of the consultation. This could be due to preconceived ideations about patient 
body image, based on their appearance, educational background and socioeconomic status. 
Conversely, young women with large tumours are still subject to simple mastectomy without 
reconstruction in many hospitals around New Zealand and Australia; even in those with 
good clinical response to neoadjuvant chemotherapy. The rationale for this practice is based 
on historic concerns about potentially leaving disease behind, treatment delays or reduced 
effectiveness of adjuvant radiotherapy in the context of immediate reconstruction. This bias 
towards mastectomy genuinely stems from the sense of ‘duty of care’ with greater focus 
on the treatment and its outcome, rather than the psychological impact of mastectomy on 
Figure 37. Pre-op left breast cancer.
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a young woman. Historic data from the National Screening Unit in the UK found that 30% 
of women undergoing mastectomy suffered from depression after treatment; equally 30% 
of women undergoing breast conservation had anxiety about recurrent cancer. The empha-
sis therefore should not be about avoiding a mastectomy but rather considering immediate 
reconstruction options in those who need mastectomy. Reverse sequencing with upfront 
radiotherapy in young patients is a relative new concept, which allows mastectomy with 
immediate autologous reconstruction, such as LD flap with implant, without compromising 
aesthetic outcome.
Increasing use of neoadjuvant chemotherapy and neoadjuvant endocrine therapy to down-
stage disease, provides adequate time to plan surgery for both patients and the treating sur-
geon [38, 39]. This allows time to organise genetic testing when indicated and an opportunity 
to improve patient health status, e.g., smoking cessation, weight loss to achieve target BMI and 
additional sessions with the clinical psychologists. In women with normal BMI and in whom 
post-operative radiotherapy is indicated, use of tissue expander as an immediate-delayed 
reconstruction, is advocated by the MD Anderson group and serves as a bridge to definitive 
reconstruction whilst preserving the mastectomy skin flap. Women are able to wake up from 
surgery without having to deal with the trauma of mastectomy.
The traditional approach of delaying reconstruction for several months (sometimes years) 
after initial cancer treatment can be detrimental to the psychosocial well-being of women 
struggling with their cancer diagnosis. In women with raised BMI, trying to lose weight 
can be a challenge and many centres would not offer delayed reconstruction unless patients 
achieved their target weight. There are limited options viz. DIEP for delayed reconstruction in 
women who have had post mastectomy radiotherapy. Some plastic surgeons would consider 
two-stage TE reconstruction after radiotherapy, but the results are variable due to limited skin 
and muscle expansion with high rates of reconstruction failure.
Figure 38. Left mastectomy and CPM with implant reconstruction.
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Delayed LD flap with implant is a good option in patients who have had post mastec-
tomy radiotherapy with less donor site morbidity compared to other forms of reconstruc-
tion. Any symmetrisation option for the native breast is probably best deferred for at least 
6 months to allow the LD flap to settle and offers the opportunity to correct any contour 
defects with lipofilling at the time of the second procedure. Preoperative CT angiogram is 
recommended in the delayed setting to confirm patent thoracodorsal pedicle prior to lifting 
the LD flap. Simple bedside examination by getting the patient tense the latissimus dorsi 
muscle would suggest intact pedicle and formal imaging can help delineate the anatomy 
adequately. The CTA occasionally picks up occult lung metastasis in patients waiting for 
delayed reconstruction (Figure 39).
Breast reconstruction following mastectomy is a complex decision and requires detailed dis-
cussion with patients to ensure adequate understanding about the complexity of surgery. It is 
important to ensure patient compliance with post-operative protocols to help minimise wound-
related complications and potentially poor outcome from reconstruction failure. Oncoplastic 
breast surgeons can offer a broad range of treatment options suitable for the individual patient 
based on cancer biology, proposed treatment plan and patient factors, such as breast shape and 
density, smoking history, BMI and other medical co-morbidities. It is recommended to have 
a minimum of two discussions prior to any reconstructive surgery with adequate clinic time 
allocated to ensure detailed discussion and patient understanding about options and operative 
choices. Use of detailed information leaflets to suit the organisation serves as a useful adjunct 
to the discussion, which patients can read at home in a less stressful environment. Additional 
consultations offer patients the opportunities to seek clarification about the proposed operation 
and the surgeon can revisit the potential risks and complications to ensure informed consent.
An experienced breast care nurse familiar with various oncoplastic procedures is invaluable 
in helping patients with preoperative counselling and decision-making. In some patients, this 
process can take a few weeks and may require input from clinical psychologists. This helps 
confirm patient’s understanding about various treatment options available, ensure decision-
making has not been unduly influenced or coerced, and minimises the risk of ‘decision-regret’ 
at a later stage.
Figure 39. CTA showing occult pulmonary metastasis.
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With the rapid global uptake of OPS, there remains a real danger of potentially worse patient 
outcome due to poor technique, improper patient selection or decision making. This is one 
specialty where good surgical skills are essential and inadequate training reflects on the 
operative outcomes with results which are glaringly obvious to both patients and clinicians.
There are well-established OPS training programmes in the UK, and post-fellowship trainees 
in Australasia are encouraged to undertake at least 2–3 years of additional clinical training 
in accredited centres. The additional training serves to up-skill their technical prowess and 
more importantly, learn the complex process of patient selection and the art of good com-
munication. The rationale for oncoplastic breast surgery as an integral part of all breast cancer 
surgery has been eloquently detailed in a review article [40].
11. Conclusion
In summary, oncoplastic breast surgery has established a firm place in the global fight against 
breast cancer. Patients should be offered the appropriate range of surgical treatment options 
instead of the conventional two-operation strategy, prevalent for the past 40 years. Clinical 
discussions are therefore more complex and additional time and expertise is required to help 
patients with decision-making. Having a well-trained and experienced breast care nurse is 
invaluable in a busy oncoplastic breast practice. A multidisciplinary team approach is an inte-
gral part of modern cancer management with early contribution of clinical psychologists in 
selected cases. Developing an oncoplastic breast surgery practice from the ground up, can be 
time-consuming and challenging. It is possible to establish a modern oncoplastic breast surgi-
cal practice despite the usual constraints of a public health system and help women achieve a 
satisfactory cosmetic outcome combined with safe oncological treatment of their breast cancer.
Surgical residents should be trained to a high standard and accreditation of oncoplastic breast 
surgical training is crucial to avoid repeating the historical mistakes of the laparoscopic era. 
The Royal Australasian College of Surgeons has recently set up an oncoplastic breast sur-
gery master’s programme for post-fellowship trainees. This will become mandatory to help 
standardise clinical knowledge, technical expertise and competency levels with peer review 
and audit. Monash University, in Melbourne, Australia, has been tasked with monitoring all 
breast implants used in reconstructive surgery to ensure a national registry service for breast 
surgical prosthetic devices.
Whilst a detailed description of oncoplastic breast surgery has not been possible, this chapter 
hopes to offer a broad overview of modern surgical practice with emphasis on implant-based 
reconstruction.
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